Noun
adalimumab (uncountable)
(pharmacology) An immunosuppressive drug (trademark Humira) that is a genetically engineered monoclonal antibody administered by subcutaneous injection to treat the symptoms of various autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and psoriasis). It acts by binding to and blocking the activity of tumor necrosis factor.
ADACTA, a phase IV study evaluating the reduction in rheumatoid arthritis disease activity during monotherapy treatment with Actemra compared to adalimumab. Source: Internet
Behrens F, et al "Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab" 2018; doi:10. Source: Internet
Investigators repeated the analysis for VOYAGE II for 112 patients who switched from adalimumab to guselkumab. Source: Internet
The distribution volume (Vss) ranged from 4.7 to 6.0 L. The systemic clearance of adalimumab is approximately 12 mL/hr. Source: Internet
Who should not use this medication: People with allergy to adalimumab must not use it. Source: Internet